NCT04596865

Brief Summary

Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the \~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a chance of cure. Unfortunately, up to 75% of patients undergoing surgery will have the cancer come back (recur). One of the reasons for this is the challenge of removing the whole tumour with some surrounding non-cancerous tissue to ensure that every tumour cell has been removed. This is difficult because there are many structures very close to the pancreas (such as the blood vessels that supply the intestines) that cannot be removed. A recent review study of \>1700 patients who had a Whipple's operation (the cancer operation that is performed to remove the head of pancreas) and found that whilst the majority of patients had cancer recurrence in distant sites (like the liver) that would not be affected by how the operation was performed, 12% of patients had the cancer recur just at the site of where the operation had been; this is known as 'local' recurrence. This suggests that a small amount of cancer was not removed at the time of surgery in these patients. Very few studies have looked at the relationship between the Computerised Tomography (CT) scan before surgery and the histology results (information about the tumour after it has been examined under the microscope) and whether this can predict exactly where the tumour recurs. If investigators can find factors that predict which patients get local only recurrence, investigators may be able to offer improved surgical techniques or other therapies during or immediately after the operation to these patients, hopefully leading to improved cure rates. This retrospective international study will look at these factors in patients who underwent a Whipple's operation for pancreatic cancer, bile duct cancer or ampullary cancer over a three year period between 2012 and 2015. Participating centres will provide data on pre-operative scans, complications around the time of surgery, any therapies (e.g. chemotherapy) that the patients had and if and where the cancer recurred. With this information, investigators hope to find ways to predict which patients will get local-only recurrence, so researchers can select them for future studies to see if additional treatments can improve the chance of cure from surgery for these patients.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,484

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2020

Typical duration for all trials

Geographic Reach
7 countries

28 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 12, 2020

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

October 15, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 22, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2022

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

1.5 years

First QC Date

October 15, 2020

Last Update Submit

November 16, 2023

Conditions

Keywords

Pancreatic cancerAmpullary cancerCholangiocarcinomaPancreaticoduodenectomyWhipple's procedureCancer recurrence

Outcome Measures

Primary Outcomes (1)

  • Patterns of disease recurrence

    Local, locoregional, distant

    Five years after date of surgery

Secondary Outcomes (2)

  • Determine if/how morbidity, mortality, disease free survival (DFS) and overall survival (OS) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:

    Pre-operative

  • Determine if/how specific patterns of recurrence (local only, distant only, synchronous local and distant) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:

    Five years after date of surgery

Study Arms (3)

Pancreatic ductal adenocarcinoma

Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015

Procedure: Pancreaticoduodenectomy

Ampullary cancer

Patients who underwent pancreaticoduodenectomy for ampullary cancer between 01/06/2010 and 31/05/2015

Procedure: Pancreaticoduodenectomy

Distal extrahepatic cholangiocarcinoma

Patients who underwent pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma between 01/06/2010 and 31/05/2015

Procedure: Pancreaticoduodenectomy

Interventions

Date of surgery 01/06/2010 - 31/05/2015

Ampullary cancerDistal extrahepatic cholangiocarcinomaPancreatic ductal adenocarcinoma

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who underwent pancreatioduodenectomy for pancreatic head malignancy (PDAC, ampullary cancer or distal extrahepatic cholangiocarcinoma) between 01/06/2010\* and 31/05/2015 inclusive in participating centres (\*01/05/2006 for Plymouth sub-study).

You may qualify if:

  • Patients who underwent pancreaticoduodenectomy for pancreatic head malignancy.
  • Date of surgery from 01/06/2010\* to 31/05/2015 inclusive (\*01/05/2006 for Plymouth sub-study).
  • Post-operative surgical histology confirmed pancreatic ductal adenocarcinoma (PDAC), ampullary adenocarcinoma (AA) or distal bile duct cholangiocarcinoma (DBCC).

You may not qualify if:

  • Postoperative surgical histology confirmed benign pathology, non-invasive neoplasia or malignant tumours other than adenocarcinoma of pancreatic, ampullary or biliary origin.
  • Patients who underwent distal pancreatectomy or total pancreatectomy as their primary procedure.
  • Patients in whom five-year follow up data is not available.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Monash Medical Centre

Clayton, Victoria, 3168, Australia

Location

Medical University Innsbruck, Anichstr. 35 A

Innsbruck, 6020, Austria

Location

Azienda Ospedaliero - Universitaria Di Sassari

Sassari, Sardinia, 07100, Italy

Location

Azienda Ospedaliero - Universitaria Policlinico Umberto I

Rome, 00161, Italy

Location

Salvador Zubirán National Institute of Health Sciences and Nutrition

Tlalpan, Mexico City, 14080, Mexico

Location

Shaukat Khanum Memorial Cancer Hospital

Lahore, Pakistan

Location

Hospital Clinic de Barcelona

Barcelona, 50009, Spain

Location

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Location

Hospital Universitario Miguel Servet

Zaragoza, Spain

Location

Ibn Sena Specialized Hospital

Khartoum, Sudan

Location

Derriford Hospital

Plymouth, Devon, PL6 8DH, United Kingdom

Location

Royal Blackburn Teaching Hospital

Blackburn, Lancashire, BB2 3HH, United Kingdom

Location

Royal Surrey County Hospital

Guildford, Surrey, GU2 7XX, United Kingdom

Location

Singleton Hospital

Swansea, Wales, SA2 8QA, United Kingdom

Location

University Hospital Coventry

Coventry, Warwickshire, CV2 2DX, United Kingdom

Location

Queen Elizabeth Hospital

Birmingham, West Midlands, B15 2TH, United Kingdom

Location

St. James's University Hospital

Leeds, West Yorkshire, LS9 7TF, United Kingdom

Location

Hull Royal Infirmary

Hull, Yorkshire, HU3 2JZ, United Kingdom

Location

Bristol Royal Infirmary

Bristol, BS2 8HW, United Kingdom

Location

Royal Infirmary of Edinburgh

Edinburgh, EH16 4SA, United Kingdom

Location

Royal Free Hospital

London, NW3 2QG, United Kingdom

Location

King's College Hospital

London, SE5 9RS, United Kingdom

Location

Hammersmith Hospital

London, W12 0HS, United Kingdom

Location

The Royal Marsden NHS Foundation Trust

London, United Kingdom

Location

Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, United Kingdom

Location

Queens Medical Centre

Nottingham, NG7 2UH, United Kingdom

Location

Churchill Hospital

Oxford, OX3 7LE, United Kingdom

Location

Northern General Hospital

Sheffield, S5 7AU, United Kingdom

Location

Southampton General Hospital

Southampton, SO16 6YD, United Kingdom

Location

MeSH Terms

Conditions

Pancreatic NeoplasmsBile Duct NeoplasmsCholangiocarcinomaCarcinoma, Pancreatic DuctalRecurrence

Interventions

Pancreaticoduodenectomy

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesBiliary Tract NeoplasmsBile Duct DiseasesBiliary Tract DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, DuctalNeoplasms, Ductal, Lobular, and MedullaryDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Digestive System Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Somaiah Aroori

    University Hospitals Plymouth NHS Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2020

First Posted

October 22, 2020

Study Start

October 12, 2020

Primary Completion

March 31, 2022

Study Completion

June 30, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations